Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Distribution Business Reform in FY2008 Was Failure: Mr Matsutani
June 29, 2009
- R&D NEWS IN BRIEF
June 29, 2009
- Injectable Risperdal to Change Treatment of Schizophrenia: Janssen
June 29, 2009
- Japan Participates in Multinational PIII Study of JAK-3 Inhibitor: Pfizer
June 29, 2009
- Eli Lilly Japan to Increase Sales of Anticancer Drugs to 30% of Total Sales
June 29, 2009
- Top Quark to Create New CRO to Undertake Asian Trials
June 29, 2009
- Glufast, Urief to Drive Kissei's Growth: Dr Ajisawa
June 29, 2009
- Asahi Kasei Medical: Planova BioEX
June 29, 2009
- Sales of Class 1 OTC Drugs Down Following Full Implementation of Amended PAL: JACDS
June 29, 2009
- REGULATORY NEWS IN BRIEF
June 29, 2009
- JACDS Approves Tadayuki Teranishi as New President
June 29, 2009
- DSUR (E2F) Fails to Reach Step 4 in Yokohama: ICH
June 29, 2009
- SELF-MEDICATION NEWS IN BRIEF
June 29, 2009
- Various Intellectual Properties Should Be Used for Lifecycle Management: Prof. Yamana
June 29, 2009
- OPINION／High Price for Executive Search in Japan
June 29, 2009
- Patents on New DDS Formulations with Known API, Indications May Become Eligible for Patent Period Restoration
June 29, 2009
- NHI Price Listing Recommended for Approval for Nine APIs
June 22, 2009
- GENERICS NEWS IN BRIEF
June 22, 2009
- Generics May Be Approved Even if Original Drugs Are Covered by Valid Use Patents
June 22, 2009
- Pharmacies Should Give List of Generics They Stock to Medical Institutions: Mr Kinoshita
June 22, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…